Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

543 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: murai h. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Infantile onset myasthenia gravis with MuSK antibodies.
Murai H, Noda T, Himeno E, Kawano Y, Ohyagi Y, Shiraishi H, Motomura M, Kira J. Murai H, et al. Neurology. 2006 Jul 11;67(1):174. doi: 10.1212/01.wnl.0000223835.51268.12. Neurology. 2006. PMID: 16832105 No abstract available.
Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group. Shinohara Y, et al. Lancet Neurol. 2010 Oct;9(10):959-68. doi: 10.1016/S1474-4422(10)70198-8. Epub 2010 Sep 15. Lancet Neurol. 2010. PMID: 20833591 Clinical Trial.
Health-related quality-of-life and treatment targets in myasthenia gravis.
Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Murai H, Imai T, Tsuda E, Konno S, Nakane S, Suzuki Y, Fujihara K, Suzuki N. Utsugisawa K, et al. Among authors: murai h. Muscle Nerve. 2014 Oct;50(4):493-500. doi: 10.1002/mus.24213. Epub 2014 Aug 30. Muscle Nerve. 2014. PMID: 24536040
Quality of life in purely ocular myasthenia in Japan.
Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, Konno S, Oji S, Nakane S, Motomura M, Suzuki N, Utsugisawa K. Suzuki S, et al. Among authors: murai h. BMC Neurol. 2014 Jul 5;14:142. doi: 10.1186/1471-2377-14-142. BMC Neurol. 2014. PMID: 24996227 Free PMC article.
Oral corticosteroid therapy and present disease status in myasthenia gravis.
Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M, Konno S, Suzuki Y, Nakane S, Fujihara K, Suzuki N, Utsugisawa K. Imai T, et al. Among authors: murai h. Muscle Nerve. 2015 May;51(5):692-6. doi: 10.1002/mus.24438. Epub 2015 Feb 4. Muscle Nerve. 2015. PMID: 25155615
Insights into the classification of myasthenia gravis.
Akaishi T, Yamaguchi T, Suzuki Y, Nagane Y, Suzuki S, Murai H, Imai T, Motomura M, Fujihara K, Aoki M, Utsugisawa K. Akaishi T, et al. Among authors: murai h. PLoS One. 2014 Sep 5;9(9):e106757. doi: 10.1371/journal.pone.0106757. eCollection 2014. PLoS One. 2014. PMID: 25192469 Free PMC article.
543 results